The global gout therapeutics market is anticipated to grow at a significant CAGR during the forecast period (2024-2031). The major factor contributing to the growth of the market include the increasing prevalence of gout across the globe. According to the National Center for Biotechnology Information (NCBI), an estimated 1 to 2% of the population is affected by gout globally. Additionally, men are more likely to get it than women with an estimated five times more in men. Furthermore, gout mostly occurs in men aged 40 and above while it usually only affects women after menopause. Hence, the increasing prevalence of gout is driving the demand for gout treatment, which in turn is driving the growth of the market.
Get Free Sample link @ https://www.omrglobal.com/request-sample/gout-therapeutics-market
Moreover, the market is segmented into drug class and application. Based on drug class, the market is sub-segmented into antihyperuricemic agents (Urate-Lowering Drugs), non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, colchicine and others. Based on application, the market is sub-segmented into acute gout and chronic gout. NSAIDs hold a prominent share in the market due to their low cost compared to other pharmacological classes coupled with their ability to relieve pain in the case of a severe attack.
Some major key players in the market include Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in April 2021, HemoShear Therapeutics, Inc. has collaborated with Horizon Therapeutics plc to identify a second drug for the treatment of gout.
Full report of Gout Therapeutics Market available @ https://www.omrglobal.com/industry-reports/gout-therapeutics-market
Market Coverage
- Segment Covered-
o By Drug Class
o By Application
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape- Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd., among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Gout Therapeutics Market Report by Segment
By Drug Class
- Antihyperuricemic Agents (Urate-Lowering Drugs)
- Non-steroidal Anti-inflammatory Drugs (NSAIDs)
- Corticosteroids
- Colchicine
- Others
By Application
- Acute Gout
- Chronic Gout
Reasons to Buying From us –
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/gout-therapeutics-market
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
